DOTATATE PET Scan for Meningioma

(DOTATATE-RT Trial)

Overseen By Sandy Chang

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: British Columbia Cancer Agency

Disqualifiers: Pregnancy, Claustrophobia, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 1

36 Participants Needed

Trial Summary

Do I need to stop my current medications for the trial?

The trial protocol does not specify whether you need to stop taking your current medications.

What data supports the effectiveness of the treatment DOTATATE-PET for meningioma?

The research shows that 68Ga-DOTATATE PET scans are more effective than traditional MRI in detecting meningiomas, especially when the tumor extends into the bone, which is crucial for planning treatment and assessing recurrence. ^{1 2 3 4 5}

How does the DOTATATE PET scan treatment differ from other treatments for meningioma?

The DOTATATE PET scan treatment is unique because it uses a special imaging technique to detect meningioma tissue by targeting somatostatin receptors, which are often present in these tumors. This method is more sensitive than traditional MRI in identifying the spread of the tumor into the bone, helping in better diagnosis and treatment planning. ^{2 3 5 6 7}

What is the purpose of this trial?

68Ga-DOTATATE-based radionuclides are a novel modality in the diagnosis and treatment of central nervous system meningioma. DOTATATE is a ligand for the SSTR (somatostatin receptor), which is expressed in meningioma but not in normal brain or bone. It is also more effective than MRI in delineating tumor, which is the current imaging standard for assessing meningioma. For radiation planning, it can help to reduce the risk of geometrical miss, identify area that require dose-escalation, and reduce dose to normal tissue. The purpose of the study is to compare the radiation therapy (RT) contouring and planning for meningioma with and without the use of 68Ga-DOTATATE-PET

Eligibility Criteria

This trial is for individuals with meningioma, a type of brain tumor. Participants should be candidates for radiation therapy and can have any grade of meningioma. Specific eligibility criteria are not provided here, but typically include age, health status, and prior treatments.

Inclusion Criteria

Able and willing to comply with the study procedures

My meningioma has not been surgically removed and needs radiation.

I need additional radiation therapy after meningioma surgery.

Exclusion Criteria

Breastfeeding or pregnancy

Unwillingness or inability to provide informed consent

I cannot stay still or am claustrophobic.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

DOTATATE-PET Scan

Participants undergo a DOTATATE-PET scan for radiation planning

1 week

1 visit (in-person)

Radiation Planning and Treatment

Radiation therapy contouring and planning for meningioma with and without the use of 68Ga-DOTATATE-PET

6-8 weeks

Follow-up

Participants are monitored for safety and effectiveness after radiation treatment

4 weeks

Treatment Details

Interventions

• DOTATATE-PET

Trial Overview The study is testing if using a DOTATATE-PET scan before radiation therapy helps better plan the treatment for meningiomas compared to standard MRI scans alone. The goal is to see if this leads to more accurate targeting of tumors while sparing healthy tissue.

Participant Groups

Group I: DOTATATE-PET scan Experimental Treatment 1 Intervention

Who Is Running the Clinical Trial?

British Columbia Cancer Agency

Lead Sponsor

Trials

181

Recruited

95,900+

Findings from Research

In a study of 20 patients with meningiomas, [68Ga]-DOTATATE PET/MRI successfully confirmed recurrent tumors in 85% of cases, demonstrating its effectiveness in distinguishing between tumor recurrence and post-treatment changes.

The novel quantitative analysis approach used in this study showed a significant difference in uptake values between meningiomas and post-treatment changes, suggesting that [68Ga]-DOTATATE PET/MRI could enhance diagnostic accuracy and treatment planning for meningioma patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Gallium-68 DOTATATE PET in the Evaluation of Intracranial Meningiomas. Ivanidze, J., Roytman, M., Lin, E., et al.[2020]

References

1. United States pubmed.ncbi.nlm.nih.gov

Gallium-68 DOTATATE PET in the Evaluation of Intracranial Meningiomas. [2020]

2. United States pubmed.ncbi.nlm.nih.gov

Improved Detection of Transosseous Meningiomas Using 68Ga-DOTATATE PET/CT Compared with Contrast-Enhanced MRI. [2019]

3. United States pubmed.ncbi.nlm.nih.gov

The Complementary Role of 68Ga-DOTATATE PET/CT in Diagnosis of Recurrent Meningioma. [2022]

4. England pubmed.ncbi.nlm.nih.gov

Evaluating diagnostic accuracy and determining optimal diagnostic thresholds of different approaches to [68Ga]-DOTATATE PET/MRI analysis in patients with meningioma. [2022]

5. United States pubmed.ncbi.nlm.nih.gov

Complementary Molecular and Metabolic Characterization of Meningiomas With DOTATATE and FDG-PET: Advancing Treatment Planning and Prognostication. [2019]

6. United States pubmed.ncbi.nlm.nih.gov

Detection of Metastatic Meningioma to the Liver Using 68Ga-DOTA-Octreotate PET/CT. [2019]

7. United States pubmed.ncbi.nlm.nih.gov

68Ga DOTATATE PET/CT of Synchronous Meningioma and Prolactinoma. [2019]